CAT-1004, an oral agent targeting NF-κB in development for...

Neuromuscular Disorders 2015 / 10 Vol. 25

CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design

Donovan, J., Sweeney, H., Vandenborne, K., Russman, B., Jirousek, M., Finkel, R.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
25
Language:
english
Journal:
Neuromuscular Disorders
DOI:
10.1016/j.nmd.2015.06.278
Date:
October, 2015
File:
PDF, 205 KB
english, 2015
Conversion to is in progress
Conversion to is failed